Related references
Note: Only part of the references are listed.The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression
Wenjing Su et al.
CANCER CELL (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Differential impact of RB status on E2F1 reprogramming in human cancer
Christopher McNair et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer
Brandon A. Mahal et al.
EUROPEAN UROLOGY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Clinical Outcomes of Chemotherapy Naive Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
Mary-Ellen Taplin et al.
JOURNAL OF UROLOGY (2017)
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield
Michael G. Holmes et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2017)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Sheng Yu Ku et al.
SCIENCE (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn et al.
CANCER CELL (2017)
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2016)
Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification
David S. Priemer et al.
ENDOCRINE PATHOLOGY (2016)
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
NATURE MEDICINE (2016)
Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
Daniel H. Hovelson et al.
NEOPLASIA (2015)
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes
Ana Aparicio et al.
CANCER DISCOVERY (2011)
Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases
Wenle Wang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501
M. A. Eisenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells
Ta-Chun Yuan et al.
ENDOCRINE-RELATED CANCER (2007)
Share Paper
